Megia Ana, Gil-Lluis Pilar, Näf Silvia, Ceperuelo-Mallafré Victoria, Gonzalez-Clemente Jose Miguel, Llauradó Gemma, Nuñez-Roa Catalina, Roche Kelly, Ballesteros Monica, Yañez Rosa Elena, Fernández-Veledo Sonia, Vendrell Joan
Endocrinology and Nutrition Section, Hospital Universitari de Tarragona Joan XXIII, Institut Investigació Sanitaria Pere Virgili, Universitat Rovira i Virgili, C/Dr. Mallafré Guasch, 4, 43007, Tarragona, Spain,
Acta Diabetol. 2015 Aug;52(4):693-700. doi: 10.1007/s00592-014-0705-9. Epub 2015 Jan 22.
BACKGROUND/OBJECTIVES: To study whether FGF21 was present in cord blood and explore its relationship with maternal variables and postnatal growth.
The study included 157 pregnant women at the beginning of the third trimester; 79 with gestational diabetes (GDM), 78 with normal glucose tolerance (NGT), and their offspring. Glucose metabolism was assessed by oral glucose tolerance test. Insulin resistance was assessed by homeostasis model assessment index-insulin resistance (HOMA-IR). FGF21 was determined in maternal plasma drawn at recruitment and in cord blood obtained at delivery. Offspring weight and height was assessed at birth and at 12, 24 and 48 months.
Maternal FGF21 was higher in gestational diabetes than in the normal glucose-tolerant group, whereas similar cord blood FGF21 levels were observed in both groups. Lower cord blood FGF21 was strongly positively correlated with maternal circulating levels. This relationship was independent of mother's prepregnancy body mass index (BMI), glucose levels and HOMA-IR. Although maternal FGF21 levels were correlated with prepregnancy BMI and HOMA-IR index, no relationship was observed between FGF21 and birth weight. However, cord blood FGF21 levels were correlated with BMI Zeta Score at 12 and 24 months, and this relationship became stronger when only the NGT group was analyzed.
FGF21 is present in human cord blood, and its levels are closely correlated with maternal levels. The association observed between cord blood FGF21 and postnatal BMI may suggest a potential role during intrauterine life that may influence future metabolic imbalance.
背景/目的：研究脐带血中是否存在成纤维细胞生长因子21（FGF21），并探讨其与母体变量及产后生长的关系。
该研究纳入了157名孕晚期初孕妇；其中79例患有妊娠期糖尿病（GDM），78例糖耐量正常（NGT），以及她们的后代。通过口服葡萄糖耐量试验评估糖代谢。通过稳态模型评估指数-胰岛素抵抗（HOMA-IR）评估胰岛素抵抗。在招募时采集的母体血浆和分娩时获得的脐带血中测定FGF21。在出生时以及12、24和48个月时评估后代的体重和身高。
妊娠期糖尿病孕妇的母体FGF21高于糖耐量正常组，而两组脐带血FGF21水平相似。较低的脐带血FGF21与母体循环水平呈强正相关。这种关系独立于母亲的孕前体重指数（BMI）、血糖水平和HOMA-IR。尽管母体FGF21水平与孕前BMI和HOMA-IR指数相关，但未观察到FGF21与出生体重之间的关系。然而，脐带血FGF21水平与12和24个月时的BMI Zeta评分相关，仅分析NGT组时这种关系更强。
FGF21存在于人类脐带血中，其水平与母体水平密切相关。脐带血FGF21与产后BMI之间的关联可能表明其在子宫内生活期间可能发挥潜在作用，这可能会影响未来的代谢失衡。
